According to information in the industry, recently, based-in Zhang Jiang gene detection company Singlera Genomics had received A round funding of 20 million dollars. This round funding was led by Lilly Asia Ventures, invested together with Green Pine Capital Partners and Calvin’s capital. The company plans to use the funding to help the development and commercialization of noninvasive gene sequencing of cancer and other genetic disease research, to promote the release of new product line of tumor diagnosis and personalized medicine.

Singlera Genomics was established by Professor Gao Yuan(Johns Hopkins University ), Professor Zhang Kun(University of California-San Diego ), together with CEO Zhang Jiangli, COO Liu Qiang and CTO Doctor Liu Rui. According to the requirement of the market and the future development, Singlera Genomics formed four product sectors: tumor diagnosis, maternal and child health care, reproductive health, and infection. Besides self-development, the company also looks for some specific partners to develop jointly in different product fields. Specifically, at present the main product and service it provides including tumor diagnosis and individualized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening and other disease diagnosis, etc.

Previously, Chairman Gao Yuan said during the interview that, as a biological information scholar, he felt more aware of the value of the Big Data Analytics of medicine and sequencing. Zhang jiangli, Co-Founder & CEO of the company once said that, “the core advantage of Singlera Genomics is its continuous technology innovation ability. We not only have two of the industry's top scientists, but also have the joint laboratory between china and the united states. Besides, there are dozens of high standard experts of biotechnology and bioinformatics work for us in China and the United States. At present, not every hospital has the ability to establish its own pathology laboratory. On one hand, we are committed to helping the capable and qualified hospitals set up their own second generation sequencing labs. We will provide a complete set of solutions, including equipment, reagents, software, technical support and subsequent continuous training; on the other hand, We will also set up our own laboratory, and work together with our strategic cooperation labs, such as Hunan Xiangya and Guangzhou Huayin to provide the third party service for the hospitals which don’t possess the ability to establish the second generation sequencing laboratory.”